| Literature DB >> 26101704 |
Yuqi He1, Jianxun Wang2, Jiheng Wang1, Victoria Yee-Wa Yung3, Emily Hsu4, Aiqin Li1, Qian Kang1, Junbiao Ma5, Qingfeng Han5, Peng Jin1, Rui Xing6, Youyong Lu6, Jianqiu Sheng1.
Abstract
Colorectal cancer remains the third most common cause of death from cancer worldwide. MicroRNA emerges as a good area of research for current cancer therapy. Here, we identified miR-135b to be a contributor to anti-apoptosis and chemoresistance in colorectal cancer. We observed high levels of miR-135b in colorectal cancer cell lines and clinical tissues, compared to colorectal epithelium cell line and noncancerous tissues. Furthermore, enforced expression of miR-135b attenuated doxorubicin-induced apoptosis in colorectal cells. (Doxorubicin alone can trigger significant apoptosis). In elucidating the molecular mechanism by which miR-135b participate in the regulation of apoptosis and chemoresistance in colorectal cancer, we discovered that large tumor suppressor kinase 2 (LATS2) is a direct target of miR-135b. The role of miR-135b was confirmed in colorectal tumor xenograft models. The growth of established tumors was suppressed by an inhibition of miR-135b expression and enhanced apoptosis was further assessed by TUNEL assay. Taken together, our results reveal that miR-135b and LATS2 axis may be a novel therapeutic target for colorectal cancer.Entities:
Keywords: LATS2; chemoresistance; colorectal cancer; miR-135b
Year: 2015 PMID: 26101704 PMCID: PMC4473317
Source DB: PubMed Journal: Am J Cancer Res ISSN: 2156-6976 Impact factor: 6.166